Vertex Pharmaceuticals reported a strong Q3 2025 performance with revenues of $3.08 billion, driven by robust growth in cystic fibrosis treatments and advancements in its renal disease pipeline.
- Achieved revenue of $3.08 billion, representing double-digit growth year-over-year.
- Continued strong uptake of ALYFTREK, qualifying 95% of CF patients for treatment, with significant clinical improvements reported.
- Progressing towards regulatory submissions for TRIKAFTA for ages 1-2, demonstrating unprecedented reductions in sweat chloride levels.
- Promising developments in the kidney portfolio, including initiation of Phase II studies for VX-407 and inaxaplin targeting serious renal diseases.
- Successful Phase IV trials for JOURNAVX in acute pain management indicate significant reductions in opioid use post-surgery.
Community Discussion